ctDNA Methylation Sequencing for Myeloma
Study Details
Study Description
Brief Summary
-
To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods for MM;
-
Carry out ctDNA-based methylation sequencing in newly diagnosed, remission, and, relapsed MM patients, to track the clonal evolution patterns; and explore the in the initial diagnosis-remission-relapse stage of MM, track the clonal evolution characteristics of methylation profiles in MM patients during the disease progression.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Myeloma This study includes a total of 60 multiple myeloma patients, and peripheral blood will be collected at newly diagnosed, remission after 4 cycles of therapy, and, relapse stage. |
Other: plasma circulation DNA methylation sequencing
10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
|
Outcome Measures
Primary Outcome Measures
- Sample Collection Completed [From Aug 31 2022 to Jun 30 2025]
When the peripheral blood samples required for the study have been collected
Eligibility Criteria
Criteria
Inclusion Criteria:
-
For myeloma patients: i) Age no less than 18 and no more than 75; ii) Diagnosed with symptomatic multiple myeloma according to IMWG consensus; iii) Provide informed consent in accordance with the declaration of Helsinki.
-
For healthy controls: i) Age no less than 18 and no more than 75; ii) Provide informed consent in accordance with the declaration of Helsinki.
Exclusion Criteria:
-
For myeloma patients: i) Insufficient amount of peripheral blood obtained; ii) Methylation sequencing failed due to technical reasons.
-
For healthy controls: i) Insufficient amount of peripheral blood obtained; ii) Methylation sequencing failed due to technical reasons.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin | China | 300020 |
Sponsors and Collaborators
- Institute of Hematology & Blood Diseases Hospital
- MethylGene Tech Co., Ltd. China
Investigators
- Principal Investigator: InsituteHBDH, Institute of Hematology and Blood Diseases Hospital,Tianjin, China, 300020
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ctDNA-MM-2022